在非小细胞肺癌的抗血管性疗法预测生物标志物的进展
1Department of Oncology, Graduate School of Qinghai University, Qinghai, China.
Cancer control : journal of the Moffitt Cancer Center
|August 28, 2024
概括
在非小细胞肺癌 (NSCLC) 抗血管性疗法的生物标志物方面的进展正在改善治疗选择. 这些包括液体活检,成像和遗传标记,以提高患者的治疗结果和生存率.
科学领域:
- 在瘤学瘤学.
- 生物标志物发现发现
- 精准医学是一门精准的医学.
背景情况:
- 抗血管生成疗法是非小细胞肺癌 (NSCLC) 的关键治疗方法.
- 预测性生物标志物对于优化治疗选择和改善患者结果至关重要.
- 个性化医疗方法需要强大的生物标志物来指导治疗决策.
研究的目的:
- 审查最近在NSCLC的抗血管性疗法预测生物标志物的进展.
- 探索液体活检,成像和遗传标记物的潜力.
- 讨论NSCLC生物标志物研究的挑战和未来方向.
主要方法:
- 对最近关于NSCLC抗血管性疗法的生物标志物的研究进行文献综述.
- 预测生物标志物的识别和分类:液体活检,成像和遗传学.
- 分析特定生物标志物的作用,如活性循环内皮细胞 (aCEC),MR-PET成像,VEGFR-1和VEGF-A.
主要成果:
- 液体活检确定了活性循环内皮细胞 (aCEC) 作为潜在的预测生物标志物.
- 高级成像 (MR-PET) 评估瘤血管生成和药物疗效.
- 遗传生物标志物,包括VEGFR-1和VEGF-A多态和血水平,在特定NSCLC患者群体中显示出治疗结果的预测价值.
结论:
- 在识别NSCLC抗血管性治疗的预测生物标志物方面取得了重大进展.
- 需要解决临床试验限制,NSCLC异质性和技术障碍等挑战.
- 未来的研究需要对个性化治疗策略进行广泛的临床验证和机制研究.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K